ArticleNeuro-oncology advances

Real-world outcomes for selumetinib in pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas in Japan: A 1-year interim analysis.

Yoshihiro Nishida et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.